Obesity is not associated with contrast nephropathy by Jaipaul, Navin et al.
© 2010 Jaipaul et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2010:6 213–217
Therapeutics and Clinical Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
213
 ORiginAL ReseARCh
open access to scientific and medical research
Open Access Full Text Article
10198
Obesity is not associated with contrast 
nephropathy
navin Jaipaul1
Rendell Manalo2
seyed-Ali sadjadi1
James McMillan1
1section of nephrology, VA Loma 
Linda healthcare system, 
2Department of Medicine, Loma  
Linda University school of Medicine, 
Loma Linda, CA, UsA
Correspondence: navin Jaipaul 
VA Loma Linda healthcare system,  
11201 Benton st (111n), Loma  
Linda, CA 92357, UsA 
Tel +1 909 583 6090 
Fax +1 909 777 3858 
email navin.jaipaul@va.gov
Background: Exposure to radiocontrast media may result in acute kidney injury (AKI) or 
traditionally defined contrast nephropathy (CN), both of which may lead to increased morbidity 
and mortality. The pathogenesis of both these variants of contrast-induced nephropathy (CIN) 
may involve inflammatory mediators that lead to renal impairment. A link between obesity 
and inflammation has been clearly established, but whether obesity is independently associated 
with CIN is unknown.
Objective: To determine whether obesity, when stratified by body mass index (BMI), is a 
risk factor for CIN in a large and hemodynamically stable population of hospitalized United 
States veterans.
Design: Retrospective chart review.
Measurements: Presence or absence of AKI or CN after intravenous radiocontrast 
administration and comparison of patient characteristics between those with versus without 
AKI or CN.
Results: The overall prevalence of AKI and CN was 16.1% and 12.6%, respectively. Patients 
with AKI or CN were comparable to those without radiocontrast injury, except that affected 
patients tended to be older and diabetic. When stratified by BMI, obesity was not found to be 
associated with the development of AKI or CN after exposure to radiocontrast.
Conclusion: Obesity does not appear to be an independent risk factor for AKI or CN after 
exposure to radiocontrast.
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Introduction
Administration of intravenous radiocontrast material may result in either acute 
kidney injury or traditionally defined contrast nephropathy, usually within the 
first 24–72 hours after the contrast is administered. Acute kidney injury has been 
defined as an abrupt (within 72 hours) reduction in kidney function or an absolute 
increase in serum creatinine of .0.3 mg/dL, compared with traditional contrast 
nephropathy which has been defined in the same context as an absolute increase in 
the serum creatinine of .0.5 mg/dL.1 Either type of kidney injury due to contrast 
may be associated with increased morbidity and mortality, in particular, as the risk of 
contrast-induced nephropathy (CIN) increases with the number of risk factors (Note: 
The term contrast-induced nephropathy used here includes both contrast-induced acute 
kidney injury and traditional contrast nephropathy). The pathogenesis of CIN may be 
mediated by various inflammatory-related factors that involve the ionic and viscous 
composition of the contrast itself, renal vasoconstriction, and direct tubular injury.2–8 Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The main risk factors for CIN that have been reported 
in the literature include chronic kidney disease (stage III 
or greater; estimated glomerular filtration rate [eGFR] 
,60 mL/min/1.73 m2), diabetes mellitus, volume depletion, 
nephrotoxic drug use (nonsteroidal anti-inflammatory drugs, 
cyclosporine, aminoglycosides), preprocedural hemodynamic 
instability, and other comorbidities (anemia, congestive heart 
failure, and hypoalbuminemia).9
Additionally, obesity may be associated with insulin 
resistance in both nondiabetic and diabetic patients, 
atherosclerosis, and the sequela of nonalcoholic fatty 
liver disease.10 Subacute and chronic inflammation often 
accompanies these obesity-related states, with elevated 
circulating levels of inflammatory markers.11,12 For example, 
F2-isoprostanes are prostaglandin-like compounds that 
serve as markers of oxidative injury, being generated from 
the free-radical initiated peroxidation of arachidonic acid.13 
Elevated levels of F2-isoprostanes have been reported in both 
patients with obesity14 and CIN.15 It is biologically plausible, 
therefore, that obesity may be independently associated with 
CIN, linked via a common inflammatory pathway. However, 
there is a paucity of data in the existing literature investigating 
whether obesity may be an additional independent risk 
factor for CIN. We therefore sought to determine whether 
obesity may be associated with CIN among a large cohort 
of hospitalized United States veterans.
Methods
study sample
We conducted a retrospective chart review of hospitalized 
patients at a single Veterans’ Affairs (VA) medical center 
in the southwestern United States. The Institutional 
Review Board at the medical center approved the study. 
By computerized data extraction, we identified all patients 
hospitalized between October 1, 2005, and September 30, 
2006, who received intravenous radiocontrast material 
(identified by Current Procedural Terminology [CPT] coding) 
and had one or more serum creatinine values within 24 hours 
preprocedure and 72 hours postprocedure. Patients undergoing 
cardiac catheterization or on dialysis were excluded. Using 
these criteria, 803 patients were ultimately included in the 
study. The following additional demographic and comorbid-
ity patient variables were extracted by computerized review: 
age, gender, race, body mass index (BMI), and the presence 
or absence of diabetes mellitus, congestive heart failure, liver 
disease, coronary artery disease, peripheral vascular disease, 
and smoking. Comorbidities were identified by International 
Classification of Disease, Ninth Revision codes. To indirectly 
measure the preprocedure volume status of our patients, 
we also extracted computerized data about the blood urea 
nitrogen (BUN) level (used in calculating the BUN/creatinine 
ratio) and systolic blood pressure on the day of the procedure, 
prior to the contrast administration.
intravenous contrast administration
At the time of this study, our medical center did not have 
a formal protocol in place for preprocedure assessment 
of patients receiving intravenous contrast. Generally, 
the referring physician would determine the need for 
periprocedure hydration with isotonic saline or use of 
N-acetylcysteine. However, all patients were administered 
nonionic, iso-osmolal contrast agents. The majority of 
patients were admitted to the hospital for a nonsepsis 
condition and underwent routine computed tomography (CT) 
of the chest, abdomen, and/or pelvis, or CT angiographic 
studies of the coronary, pulmonary, abdominal, or lower 
extremity vasculature.
Measurements
Two trained reviewers used the VA electronic medical record 
to identify the date of the procedure involving intravenous 
radiocontrast administration and abstract the most recent 
serum creatinine value, usually the day before the procedure 
(baseline level), and highest serum creatinine value within 
72 hours after the procedure (peak level). Using the 
predefined criteria for acute kidney injury and traditional 
contrast nephropathy previously mentioned, these primary 
outcomes were dichotomized as present or absent according 
to the absolute change between peak and baseline serum 
creatinine values. Obesity was categorized according to stage 
of BMI: Stage 0, Underweight, BMI , 20; Stage 1, Normal, 
BMI , 25; Stage 2, Overweight, BMI 25–30; Stage 3, Obese, 
BMI 31–35; Stage 4, Morbidly Obese, BMI . 35.
statistical power calculation
Using a conservative 3% estimate for the difference in 
the prevalence rate of contrast-induced nephropathy 
between obese and nonobese individuals (13% obese vs 
10% nonobese), and a prespecified alpha level of 0.05, we 
determined a minimal needed sample size of 146 patients 
in each group of this population subset in order to achieve 
a power of 80%.
statistical analysis
Clinical and demographic characteristics were com-
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acute kidney injury or traditional contrast nephropathy, 
using χ2 tests for dichotomous variables and t-tests for 
continuous variables. Factors significantly associated with 
contrast-induced nephropathy in bivariate analysis were 
entered in logistic regression models to determine independent 
predictors of contrast nephropathy. We considered P values 
,0.05 to be significant. Inter-rater agreement on the primary 
outcomes of interests between the reviewers was assessed 
using the k statistic on a 10% subset. All statistical analysis 
was performed with the SPSS statistical package (version 
17.0; SPSS Inc., Chicago, IL).
Results
The baseline characteristics of our study population 
are shown in Table 1. In this predominantly Caucasian 
male study population, diabetes was the most common 
comorbid condition, affecting 32% of the population. Other 
comorbidities examined included heart failure (14%), liver 
disease (8%), coronary artery disease (14%), peripheral 
vascular disease (25%), and cigarette smoking (4%). The 
majority of the patients were overweight with an average 
BMI of 27.3. Approximately 14% of patients were obese 
(BMI 31–35), while 9% were morbidly obese (BMI . 35). 
A minority of patients were underweight (BMI , 20). Our 
study population represented a hemodynamically stable 
cohort of patients regardless of the presence or absence of 
CIN, as evidenced by a mean BUN/creatinine ratio below 20 
and mean systolic blood pressure above 120 mmHg across 
all groups studied.
The overall prevalence of acute kidney injury (AKI) and 
traditional contrast nephropathy (CN) was 16.1% and 12.6%, 
respectively. Patients with AKI or CN were comparable 
to those without radiocontrast injury, except that affected 
patients tended to be older and diabetic, P , 0.05 (Table 1). 
Specifically, each additional year of age was associated with a 
statistically significant 2% increase in the odds of AKI (odds 
ratio [OR] = 1.02; 95% confidence interval [CI]: 1.01–1.03), 
and the presence of diabetes was associated with a statistically 
significant 56% increased odds of CN (OR = 1.56; 95% CI: 
1.01–2.39) (Table 2). When stratified by BMI, obesity was 
not found to be associated with the development of AKI 
or CN after exposure to radiocontrast (Table 1). Being 
Table 1 Comparison of patients with versus without Cn or AKi after intravenous contrast exposure
Characteristic No CN  
(N = 702)
CN  
(N = 101)
P value No AKI  
(N = 674)
AKI  
(N = 129)
P value
Age, years 64.6 (±13.1) 67.1 (±12.8) 0.07 64.5 (±12.9) 67.1 (±12.7) 0.04
Male gender, n 667 96 0.99 639 124 0.53
White race, n 564 84 0.67 541 107 0.42
Diabetes mellitus, n 218 42 0.03 209 51 0.06
heart failure, n 98 15 0.81 92 21 0.43
Liver disease, n 59 5 0.23 58 6 0.13
Coronary artery disease, n 95 18 0.25 90 23 0.18
Peripheral vascular disease, n 176 26 0.88 164 38 0.22
smoking, n 29 5 0.70 28 6 0.80
BMi, kg/m2  27.3 (±6.9) 27.4 (±6.6) 0.88 27.3 (±7.0) 27.6 (±6.5) 0.64
Obesity staging, n 0.93 0.88
  stage 0 (BMi , 20) Underweight 78 9 0.49 76 11 0.29
  stage 1 (BMi 20–25) normal 208 30 0.86 201 37 0.98
  stage 2 (BMi 25–30) Overweight 211 33 0.28 203 41 0.21
  stage 3 (BMi 31–35) Obese 128 17 0.26 120 25 0.05
  stage 4 (BMi . 35) Morbidly Obese 77 12 0.95 74 15 0.96
systolic blood pressure, mmhg 124.7 (±20.5) 126.1 (±24.8) 0.56 124.7 (±20.5) 125.7 (±23.7) 0.63
Blood urea nitrogen/creatinine ratio 15.5 (±8.3) 17.1 (±8.7) 0.07 15.4 (±8.2) 17.2 (±8.9) 0.07
Baseline creatinine, mg/dL 1.0 (±0.3) 1.0 (±0.3) 0.08 1.0 (±0.3) 1.0 (±0.3) 0.67
Peak creatinine,* mg/dL 1.0 (±0.3) 1.4 (±0.5) ,0.01 1.0 (±0.3) 1.4 (±0.5) ,0.01
Notes: *Within 72 hours postcontrast.
Abbreviations: AKi, acute kidney injury; BMi, body mass index; Cn, contrast nephropathy.
Table 2 Logistic regression models for odds ratio estimates of 
Cn or AKi associated with age and diabetes mellitus
Variable CN AKI
95% CI 95% CI
OR Lower  Upper OR Lower Upper
Age 1.01 1.00 1.03 1.02 1.01 1.03
Diabetes 1.56 1.01 2.39 1.43 1.00 2.11
Abbreviations: AKI, acute kidney injury; CI, confidence interval; CN, contrast 
nephropathy; OR, odds ratio.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  underweight was also not associated with the development 
of AKI or CN after contrast exposure (Table 1). Complete 
agreement between the two reviewers regarding the develop-
ment of AKI or CN was substantial (98%).
Discussion
The focus of this study was to determine whether obesity, 
when stratified by BMI, is a risk factor for CIN in a large 
and hemodynamically stable population of hospitalized 
United States veterans. For this reason, we purposefully 
excluded patients undergoing cardiac catheterization because 
of increased risk of hemodynamic instability in this subset 
of hospitalized patients. Hemodynamic alterations in these 
patients would predispose to other forms of hypoperfusion-
induced kidney injury that would be indistinguishable from 
contrast-induced nephropathy by the defined criteria. Despite 
exclusion of these patients, our study was still more than 
adequately powered to detect even a conservative estimate 
for the difference in the prevalence rate of contrast-induced 
nephropathy between obese and nonobese individuals, as 
noted in the Methods section.
The prevalence rates of AKI and CN observed in this 
study are consistent with those published previously in 
the literature.1 In addition, we found that older age and the 
presence of diabetes are significantly associated with the 
development of CIN. These are also known associations 
that have been previously reported in the literature,1 and we 
verified their independent association in the direction and 
magnitude expected based on logistic regression models 
(Table 2). In our study, however, obesity was not found to 
be independently associated with the development of CIN. 
This lack of a relationship between obesity and CIN persisted 
regardless of stage of obesity or level of kidney function. 
Despite the biological plausibility of an inflammatory role 
linking obesity to CIN, the absence of an observed association 
suggests that increased tissue adiposity alone is not sufficient 
to increase the risk of CIN, or that other unaccounted fac-
tors may mitigate the effects of increased tissue adiposity 
on the kidney after contrast exposure. For instance, obesity 
is known to induce glomerular hyperfiltration which may 
enhance tubular sodium reabsorption and contribute to a 
transiently volume expanded state.16 Plausibly, therefore, 
such a volume expanded state might reduce the risk of CIN. 
It is also well known that GFR estimated by the Modification 
of Diet in Renal Disease (MDRD) formula tends to under-
estimate actual GFR in obese individuals, and therefore, it 
is possible that some of our patients had higher GFRs and 
were at lower risk for the development of CIN.17,18 Along this 
line of thought, however, it is important to point out that we 
neither observed an increased risk of obesity with CIN, nor 
a protective effect of obesity on CIN. Similarly, we observed 
no association of being underweight with the risk of CIN, 
even though underweight individuals may have diminished 
physiologic reserve.
It is also interesting to note that in this study, obesity 
was not a surrogate marker of diabetes as may be expected. 
Nevertheless, we believe that the results of our study are 
valid due to the fact that we observed prevalence rates of 
CIN and expected associations of known variables with CIN 
as previously mentioned.
Limitations of this study include its observational nature 
in a single medical center and lack of generalizability to 
other populations. Additionally, we did not have access 
to information about concurrent medication use such 
as the dose of contrast given, or statin therapy which is 
known to have anti-inflammatory properties.19 However, 
the potential anti-inflammatory effects of statin therapy 
on the kidney, and specifically CIN, remain still largely 
speculative and unproven. In fact, recent observational data 
suggests that statin usage prior to primary percutaneous 
coronary intervention is not associated with reduction in 
CIN.20 Similarly, the benefit of periprocedure treatment 
with N-acetylcysteine in reducing CIN is unproven,21 and 
we did not have access to information about its use among 
our study population. We were also unable to gauge directly 
the volume status of the patients included in the study. 
However, we evaluated reasonable surrogate markers for 
preprocedure volume status such as BUN/creatinine ratio 
and systolic blood pressure. These measurements suggested 
that our study population was adequately volume replete 
and hemodynamically stable prior to the administration of 
intravenous contrast.
Despite the aforementioned limitations of our study, 
this particular population of patients is representative of a 
typical cohort at risk for CIN, and our finding that obesity 
is not an independent risk factor for contrast nephropathy 
should reassure medical providers of no added risk for 
kidney injury after intravenous contrast administration due 
to obesity alone.
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